Diabetes mellitus accelerates left ventricular diastolic dysfunction through activation of the renin-angiotensin system in hypertensive rats

Hypertension Research

Volumn 32, Issue 6, 2009, Pages 472-480

  Fukui, Shigefumi ^a   Fukumoto, Yoshihiro ^a   Suzuki, Jun ^a   Saji, Kenya ^a   Nawata, Jun ^a   Shinozaki, Tsuyoshi ^a   Kagaya, Yutaka ^a   Watanabe, Jun ^a   Shimokawa, Hiroaki ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ANGIOTENSIN 2 RECEPTOR; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE; OLMESARTAN; SODIUM CHLORIDE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; STREPTOZOCIN DIABETES; SYSTOLE;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOTTING, WESTERN; COLLAGEN; CYTOKINES; DIABETES MELLITUS; ECHOCARDIOGRAPHY; HEMODYNAMICS; HYPERTENSION; MALE; MYOCARDIUM; ORGAN SIZE; OXIDATIVE STRESS; RATS; RATS, INBRED DAHL; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 68249160936     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.43     Document Type: Article

References (50)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith Jr SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005; 112: e154-e235.
2. Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
3. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-2150.
4. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, van Gilst WH, Hobbs FD, Korewicki J, Madeira HC, Preda I, Swedberg K, Widimsky J. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 2002; 360: 1631-1639.
5. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
6. Piccini JP, Klein L, Gheorghiade M, Bonow RO. New insights into diastolic heart failure: Role of diabetes mellitus. Am J Med 2004; 116 (Suppl 5A): 64S-75S.
7. O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000; 86: 863-867.
8. Parker AB, Yusuf S, Naylor CD. The relevance of subgroup-specific treatment effects: The Studies Of Left Ventricular Dysfunction (SOLVD) revisited. Am Heart J 2002; 144: 941-947.
9. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci 2001; 69: 527-542.
10. Hoit BD, Castro C, Bultron G, Knight S, Matlib MA. Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail 1999; 5: 324-333.
11. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: The Strong Heart Study. J Am Coll Cardiol 2001; 37: 1943-1949.
12. Shiomi T, Tsutsui H, Ikeuchi M, Matsusaka H, Hayashidani S, Suematsu N, Wen J, Kubota T, Takeshita A. Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 2003; 42: 165-172.
13. Matsusaka H, Kinugawa S, Ide T, Matsushima S, Shiomi T, Kubota T, Sunagawa K, Tsutsui H. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction. J Cardiovasc Pharmacol 2006; 48: 95-102.
14. Given MB, Lowe RF, Gelvin CR, Sander GE, Giles TD. Preservation of left ventricular function and coronary flow by angiotensin I-converting enzyme inhibition in the hypertensive-diabetic Dahl rat. Am J Hypertens 1994; 7: 919-925.
15. Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, Miwa T, Masuyama T, Yamamoto K, Hori M. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 2007; 25: 455-461.
16. Inagaki K, Koyanagi T, Berry NC, Sun L, Mochly-Rosen D. Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension 2008; 51: 1565-1569.
17. Hoshi-Fukushima R, Nakamoto H, Imai H, Kanno Y, Ishida Y, Yamanouchi Y, Suzuki H. Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure. Am J Nephrol 2008; 28: 413-423.
18. Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, Ohta J, Shiroto T, Shirato K, Minegishi N, Shimokawa H. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007; 115: 2022-2032.
19. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H. Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 2008; 51: 317-326.
20. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, Ono K, Kuzuya T, Hirota S, Koyama T, Miwa T, Hori M. Development of different phenotypes of hypertensive heart failure: Systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18: 111-120.
21. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
22. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa N, Kondo H, Ono K, Kuzuya T, Sugawara M, Hori M. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 2000; 36: 2333-2338.
23. Yamamoto K, Masuyama T, Doi Y, Naito J, Mano T, Kondo H, Nagano R, Tanouchi J, Hori M, Kamada T. Noninvasive assessment of left ventricular relaxation using continuous-wave Doppler aortic regurgitant velocity curve. Its comparative value to the mitral regurgitation method. Circulation 1995; 91: 192-200.
24. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767-775.
25. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-999.
26. Fukumoto Y, Deguchi JO, Libby P, Rabkin-Aikawa E, Sakata Y, Chin MT, Hill CC, Lawler PR, Varo N, Schoen FJ, Krane SM, Aikawa M. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation 2004; 110: 1953-1959.
27. Kitamura M, Shimizu M, Kita Y, Yoshio H, Ino H, Misawa K, Matsuyama T, Mabuchi H. Quantitative evaluation of the rate of myocardial interstitial fibrosis using a personal computer. Jpn Circ J 1997; 61: 781-786.
28. Sauzeau V, Sevilla MA, Rivas-Elena JV, de Alava E, Montero MJ, Lopez-Novoa JM, Bustelo XR. Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med 2006; 12: 841-845.
29. Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest 1976; 58: 751-760.
30. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-2871.
31. Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, Miwa T, Takeda H, Hori M. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: Different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 2001; 37: 293-299.
32. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 1995; 91: 161-170.
33. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999; 100: 2093-2099.
34. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab Invest 2000; 80: 513-527.
35. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, Ohtani T, Miwa T, Hori M, Masuyama T. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004; 43: 686-691.
36. Weber KT. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation 1997; 96 4065-4082.
37. Weber KT. Targeting pathological remodeling: Concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-1345.
38. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I, Diez J. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17: 107-114.
39. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 1999; 96: 10857-10862.
40. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002; 105: 293-296.
41. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 2003; 23: 776-782.
42. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, Tada M, Hori M. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105: 509-515.
43. Yamamoto K, Redfield MM, Nishimura RA. Analysis of left ventricular diastolic function. Heart 1996; 75: 27-35.
44. 2+ regulatory proteins and extracellular matrix. J Hypertens 2003; 21: 1737-1745.
45. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heaPt in diabetes: Part II: potential mechanisms. Circulation 2002; 105: 1861-1870.
46. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
47. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
48. Malhotra R, Sadoshima J, Brosius III FC, Izumo S. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ Res 1999; 85: 137-146.
49. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25 543-567.
50. Stewart RA, Joshi J, Alexander N, Nihoyannopoulos P, Oakley CM. Adjustment for the influence of age and heart rate on Doppler measurements of left ventricular filling. Br Heart J 1992; 68 608-612.